Published in Cancer Res on June 15, 1994
Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A (1999) 2.01
Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood (2010) 0.95
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem (2007) 0.95
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells. Clin Mol Pathol (1995) 0.75
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost (2011) 2.14
Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood (1992) 2.09
Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med (1998) 1.98
A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia (1987) 1.78
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am (1994) 1.62
Analysis of the GAL3 signal transduction pathway activating GAL4 protein-dependent transcription in Saccharomyces cerevisiae. Genetics (1990) 1.58
Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene (2000) 1.54
Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb Res (2003) 1.51
Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Eur J Vasc Endovasc Surg (1995) 1.47
Extracranial internal carotid artery stenosis as a cause of cortical subarachnoid hemorrhage. AJNR Am J Neuroradiol (2011) 1.46
A study of pancreatic enzymes as a factor in the pathogenesis of disseminated intravascular coagulation during acute pancreatitis. Surgery (1971) 1.45
Multiple proline substitutions cumulatively thermostabilize Bacillus cereus ATCC7064 oligo-1,6-glucosidase. Irrefragable proof supporting the proline rule. Eur J Biochem (1994) 1.34
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res (1996) 1.33
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A (1997) 1.33
Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest (1969) 1.33
Age is not a contraindication to pancreaticoduodenectomy. Am Surg (2001) 1.21
Escherichia coli NifS-like proteins provide selenium in the pathway for the biosynthesis of selenophosphate. J Biol Chem (2000) 1.20
The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost (2009) 1.18
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest (1995) 1.17
Origin of fibrinolytic activity in cultures of the human kidney. J Lab Clin Med (1967) 1.17
Tissue fibrinolytic activity studied by a histochemical method. Fed Proc (1990) 1.15
Fibrinolytic activity in experimental intracerebral hematoma. J Neurosurg (1988) 1.15
Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation. Diabetes (1972) 1.13
Current concepts of warfarin therapy. Arch Intern Med (1986) 1.13
Binding of cationic alpha-helical peptides to plasmid DNA and their gene transfer abilities into cells. J Biol Chem (1997) 1.13
The role of fibrinogen in renal disease. I. Production of experimental lesions in mice. J Lab Clin Med (1969) 1.10
Increased platelet aggregation in diabetes mellitus. J Lab Clin Med (1972) 1.08
Structure of a NifS homologue: X-ray structure analysis of CsdB, an Escherichia coli counterpart of mammalian selenocysteine lyase. Biochemistry (2000) 1.08
Fibrinolytic activity in thrombosed veins. Circ Res (1965) 1.07
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost (2004) 1.06
Fibrinolytic activity in the normal and inflamed rectal mucosa. Scand J Gastroenterol (1969) 1.03
Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care (1986) 1.03
Demonstration of cellular fibrinolytic activity by the histochemical fibrin slide technique. Lab Invest (1967) 1.03
Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia. Blood (1969) 1.03
Effects of synthetic model peptides resembling the extension peptides of mitochondrial enzyme precursors on import of the precursors into mitochondria. J Biochem (1985) 1.02
Observation of electron-antineutrino disappearance at Daya Bay. Phys Rev Lett (2012) 1.00
Long-term follow-up results of anterior interbody fusion applied for cervical myelopathy due to ossification of the posterior longitudinal ligament. Spine (Phila Pa 1976) (2001) 1.00
Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost (1999) 0.99
The pathogenesis of thrombotic thrombocytopenic purpura. Semin Thromb Hemost (1979) 0.99
Arterial thrombosis in scleroderma. Br J Dermatol (1975) 0.98
High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension (1993) 0.97
Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA (1981) 0.97
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol (1989) 0.96
Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma. Strahlenther Onkol (2013) 0.95
Mixed hepatoblastoma in an adult--a case report and literature review. J Korean Med Sci (1997) 0.94
Characterization of potent fibrinolytic enzymes in earthworm, Lumbricus rubellus. Biosci Biotechnol Biochem (1993) 0.94
Malignant lymphoma of the bone associated with systemic sarcoidosis. Intern Med (2001) 0.93
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate (1991) 0.93
Atypical hairy cell leukemia. Arch Pathol Lab Med (2000) 0.92
Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol (1997) 0.91
Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed Proc (1987) 0.90
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res (1994) 0.90
Relationship between antimicrobial activity and amphiphilic property of basic model peptides. Biochim Biophys Acta (1986) 0.90
Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet (1998) 0.90
Behavioral correlates of plasma sex hormones and their relationships with plasma lipids and lipoproteins in Japanese men. Atherosclerosis (1997) 0.89
Hemodialysis-exchange transfusion for treatment of thrombotic thrombocytopenic purpura. JAMA (1980) 0.89
Incidence of venous thromboembolism following major surgery in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost (2014) 0.88
Optimization of hydrophobic domains in peptides that undergo transformation from alpha-helix to beta-fibril. Bioorg Med Chem (1999) 0.88
Mutational analysis of designed peptides that undergo structural transition from alpha helix to beta sheet and amyloid fibril formation. Structure (2000) 0.88
Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. J Vasc Surg (1997) 0.87
Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res (1985) 0.87
Broad substrate specificity of snake venom fibrinolytic enzymes: possible role in haemorrhage. Toxicon (1992) 0.87
Demonstration of an active component of inter-alpha-trypsin inhibitor in the brains of Alzheimer type dementia. Biochem Biophys Res Commun (1991) 0.87
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
Reinfusion of postoperative wound drainage in total joint arthroplasty. Red blood cell survival and coagulopathy risk. J Arthroplasty (1994) 0.86
Disseminated intravascular coagulation after excision of giant hemangioma. Am J Surg (1974) 0.86
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics. Control Clin Trials (1984) 0.86
Cyclic peptides. XVI. Syntheses of AM-toxin I analogs containing a lower or higher homolog of the component L-2-amino-5-(p-methoxyphenyl)pentanoic acid residue. Int J Pept Protein Res (1984) 0.86
Studies on blood coagulation and fibrinolysis in patients bitten by Bothrops jararaca (jararaca). Thromb Haemost (1990) 0.86
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer (1998) 0.86
Synthetic inhibitors of fibrinolysis: in vitro and in vivo mode of action. Ann N Y Acad Sci (1968) 0.86
The role of fibrinogen in renal disease. II. Effect of anticoagulants and urokinase on experimental lesions in mice. J Lab Clin Med (1969) 0.86
Increased expression and localization of a serine protease inhibitor, protease nexin-1 (PN-1), in the ovary and uterus during implantation in rat. Thromb Res (2001) 0.85
Immunologic identity of plasminogen activator in human urine, heart, blood vessels, and tissue culture. J Lab Clin Med (1974) 0.85
Characterization of a cathepsin-H-like enzyme from a human melanoma cell line. Int J Cancer (1991) 0.85
Expression of endothelial cell-associated molecules in AML cells. Leukemia (2002) 0.85
Incidence of pregnancy-associated venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost (2011) 0.84
Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol (1987) 0.84
Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol (2002) 0.84
A high-throughput screening utilizing intramolecular fluorescence resonance energy transfer for the discovery of the molecules that bind HIV-1 TAR RNA specifically. Bioorg Med Chem Lett (2000) 0.84
Effects of Ancrod (Arvin) in mice: studies of plasma fibrinogen and fibrinolytic activity. Br J Haematol (1973) 0.84
Fluid pressure of capsules implanted into dog brain. Jpn J Physiol (1974) 0.84
Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol (2012) 0.84
Clearance and distribution of acid-stable trypsin inhibitor (ASTI). Enzyme (1989) 0.83
Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. Kidney Int (2006) 0.83
Gene cloning, purification, and characterization of two cyanobacterial NifS homologs driving iron-sulfur cluster formation. Biosci Biotechnol Biochem (2000) 0.83
Fibrinolysis in the anterior segment of the eye. Arch Ophthalmol (1967) 0.83
The role of fibrinogen in renal disease. 3. Fibrinolytic and anticoagulant treatment of nephrotoxic serum nephritis in mice. J Lab Clin Med (1969) 0.83
Prothrombin and factor X activating properties of Bothrops erythromelas venom. Ann Trop Med Parasitol (1992) 0.83
Distribution of JC virus DNA in peripheral blood lymphocytes of hematological disease cases. Intern Med (1999) 0.83
Tissue repair in presence of locally applied inhibitors of fibrinolysis. Exp Mol Pathol (1969) 0.83
Hypertrophy of the posterior longitudinal ligament is a prodromal condition to ossification: a cervical myelopathy case report. Spine (Phila Pa 1976) (2001) 0.82
Histochemical study of fibrinolytic activity in the rat uterus in normal and hormonally induced estrus. Am J Obstet Gynecol (1966) 0.82
Quantitation of fibrinolytic activity in venous and prosthetic arterial grafts. Arch Surg (1974) 0.82
Delta and mu opiate receptor probes: fluorescent enkephalins with high receptor affinity and specificity. FEBS Lett (1985) 0.82
Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma (2006) 0.82
Construction of peptides with nucleobase amino acids: design and synthesis of the nucleobase-conjugated peptides derived from HIV-1 Rev and their binding properties to HIV-1 RRE RNA. Bioorg Med Chem (2001) 0.82